Anthrax Vaccine Market Report 2026

Anthrax Vaccine Market Overview

• Anthrax Vaccine market size has reached to $11.77 billion in 2025 • Expected to grow to $14.49 billion in 2030 at a compound annual growth rate (CAGR) of 4.1% • Growth Driver: Rising Infectious Diseases Fueling Growth In The Anthrax Vaccine Market • Market Trend: Advancements And FDA Approvals In The Anthrax Vaccine Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Anthrax Vaccine Market?

The anthrax vaccine is a medical product designed to provide immunity against anthrax, a severe infectious disease caused by the bacterium Bacillus anthracis. The vaccine comprises an inactivated form of the anthrax bacterium or its components, stimulating the body's immune system to produce antibodies against anthrax toxins. The anthrax vaccine is typically administered through injections, with initial doses followed by booster shots to maintain immunity over time. The main vaccine types of the anthrax vaccine are the cell-free protective antigen (PA) vaccine and the live attenuated vaccine. A cell-free protective antigen (PA) vaccine is made in a lab without the use of live bacteria by synthesizing the anthrax bacteria's protective antigen (PA) protein. The applications include animal and human use, and they are distributed through various channels such as hospitals, pharmacies, and others.

What Is The Anthrax Vaccine Market Growth Forecast?

The anthrax vaccine market size is expected to see steady growth in the next few years. It will grow to $14.49 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to development of recombinant and next-generation vaccines, rising demand for human and animal prophylaxis, advancements in vaccine delivery technologies, expansion of biodefense programs, collaborations between pharma and defense sectors. Major trends in the forecast period include advanced vaccine formulations, expanded immunization programs, cold chain & storage innovations, biodefense & pandemic preparedness, government & military vaccination initiatives.

Global Anthrax Vaccine Market Segmentation

1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine, Live Attenuated Vaccine 2) By Application Type: Animal Use, Human Use 3) By Distribution Channel: Hospitals, Pharmacies, Other Distribution Channels Subsegments: 1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine, Adjuvanted rPA Vaccine 2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine, Genetically Modified Live Attenuated Vaccine

What Is The Driver Of The Anthrax Vaccine Market?

The rising prevalence of infectious diseases is expected to propel the growth of the anthrax vaccine market going forward. Infectious diseases refer to illnesses caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, which can spread directly or indirectly from one person to another, often leading to symptoms ranging from mild to severe and sometimes fatal, depending on the pathogen and the individual's immune response. The prevalence of infectious diseases is due to shifts in the demographics of the world's population, urbanization, changes in the environment and land use, and changes in human behavior. The anthrax vaccine is primarily utilized to protect against anthrax, and its potential for broader use in preventing other infectious diseases is being explored through research into its immunogenic properties and adaptability. For instance, in February 2023, according to the Council on Foreign Relations, a US-based nonprofit organization, up to 75% of newly discovered or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases had zoonotic origins. Further, worldwide, zoonoses cause 2.7 million human fatalities and 2.5 billion episodes of disease in people each year. Therefore, the rising prevalence of diseases is driving the growth of the anthrax vaccine industry.

Key Players In The Global Anthrax Vaccine Market

Major companies operating in the anthrax vaccine market are Emergent BioSolutions Inc., Indian Immunologicals Limited, GC Biopharma, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company Inc., Botswana Vaccine Institute, VECOL S.A., Biological E Limited, Serum Institute of India Pvt. Ltd., Panacea Biotec Ltd., China National Biotec Group, Sinovac Biotech Ltd., Instituto Butantan, Razi Vaccine and Serum Research Institute, Federal State Unitary Enterprise Microgen, KM Biologics Co. Ltd., Haffkine Bio-Pharmaceutical Corporation Ltd.

Global Anthrax Vaccine Market Trends and Insights

Major companies operating in the anthrax vaccine market are focused on developing innovative products and getting FDA approvals for their vaccines to ensure safety, efficacy, and availability to those at risk of exposure to anthrax. FDA approval ensures the vaccine is rigorously tested in clinical trials and proven safe for public use. This helps protect individuals from potential adverse effects. For instance, in July 2023, Emergent BioSolutions Inc., a US-based biopharmaceutical company, received approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, from the U.S. Food and Drug Administration (FDA). The approval was predicated on information from a Phase 2 trial evaluating Cyfendus's non-interference with antibacterial medications and Phase 3 clinical research comparing the immunogenicity and safety of the vaccine to BioThrax, the previous anthrax vaccine. Further, developing safer and more effective adjuvants is imperative to address reactogenicity-related problems and enhance the general efficiency of anthrax vaccines.

What Are Latest Mergers And Acquisitions In The Anthrax Vaccine Market?

In April 2025, Green Cross Corporation, a South Korea-based biopharmaceutical company that develops anthrax and other vaccines and biologics, partnered with the Korea Disease Control and Prevention Agency (KDCA) for the development and approval of a recombinant anthrax vaccine. With this partnership, GC Biopharma and KDCA aim to leverage their respective expertise in biotechnology and public health, combining GC Biopharma’s recombinant-protein vaccine technology with KDCA’s regulatory and disease prevention capabilities to provide a safe and effective anthrax vaccine, ultimately strengthening national biodefense preparedness. Korea Disease Control and Prevention Agency (KDCA) is a South Korea-based government agency responsible for disease control, prevention, and public health management.

Regional Insights

North America was the largest region in the anthrax vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Anthrax Vaccine Market?

The anthrax vaccine market consists of sales of avirulent, nonencapsulated bacillus anthracis microaerophilic cultures, aluminum, benzethonium chloride, and formaldehyde. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Anthrax Vaccine Market Report 2026?

The anthrax vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the anthrax vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.